Randomized, Open, Multicentre, National Superiority Clinical Trial to Assess the Combination of Fixed Dosage of Dipyrone and Codeine Compared to the Isolated Use of Components in the Control of Moderate to Severe Pain After Open Pelvic-abdominal Surgery.

Phase III clinical trial, multicentre of superiority, randomized, open, parallel groups, with active control and use of postoperative oral medication (multiple doses of medication).

Start Date16 Mar 2023

Sponsor / Collaborator

Brainfarma Indústria Química e Farmacêutica SA

NCT04874675 / SuspendedNot ApplicableIIT

A Randomised Control Clinical Trial Comparing Diclofenac / Acetaminophen /Codeine and Ibuprofen/Acetaminophen/Codeine Combination for Pain Management After Third Molars Surgery

Randomised control clinical trial to compare which combination of analgesics in effective in pain management after third molar extraction of wisdom teeth. The study will assess post operative pain after third molar extraction of two groups of study participants who will be given one of the two combinations of Diclofenac/ acetaminophen/codeine and ibuprofen/acetaminophen/codeine .

Start Date01 Mar 2023

Sponsor / Collaborator

University of Zimbabwe

NCT04202406 / CompletedNot ApplicableIIT

Effect of Preoperative Acetaminophen-Codeine-Caffeine Combination on Inferior Alveolar Nerve Block Success in Patients With Symptomatic Irreversible Pulpitis: Randomized Double-blind Controlled Trial

The aim of the study is to evaluate the effect of preoperative administration of acetaminophen- codeine -caffeine combination on the success of the inferior alveolar nerve block versus bacetaminophen alone or placebo in patients with symptomatic irreversible pulpitis.

Start Date09 Jan 2021

Sponsor / Collaborator

Cairo University

100 Clinical Results associated with Codeine Phosphate Hydrate

100 Translational Medicine associated with Codeine Phosphate Hydrate

100 Patents (Medical) associated with Codeine Phosphate Hydrate

469

Literatures (Medical) associated with Codeine Phosphate Hydrate

01 Oct 2024·Journal of Gastrointestinal Oncology

Patient-controlled analgesia with hydromorphone treatment for advanced colon cancer with severe pain in an older adult patient: a case report and literature review

Article

Author: Zheng, Mao-Dong ; Wang, Yu ; Ma, Huan ; Qiao, Ting-Ting ; Krasovitsky, Michael S. ; Karlekar, Mohana ; Krasovitsky, Michael S ; Tatar, Cihad ; Yan, Juan ; Wang, Ze-Yu ; Li, Yan-Xia

Background:

Unrelieved cancer pain can seriously reduce patients' quality of life. Hydromorphone based patient-controlled analgesia (PCA) is widely used in surgery. In recent years, it has also gained attention in the field of cancer pain. We report the case of an older patient with refractory pain secondary to colorectal cancer for whom PCA therapy led to improved symptomatic outcomes.

Case Description:

We present the case of a 79-year-old male with severe pain from advanced colon cancer. After receiving anti-cancer therapy for 7 years, the patient developed pain in the right groin with a pain score of 7/10. The results of whole-body bone imaging suggested the underlying cause to be a pelvic osseous metastasis. Contemporaneous computed tomography (CT) scanning confirmed disease progression in previously noted non-osseous sites of disease. Systemic therapy with bevacizumab, oxaliplatin, and raltitrexed was commenced. For pain palliation, the patient was treated with morphine hydrochloride tablets, morphine hydrochloride injections, compound codeine phosphate and ibuprofen sustained release tablets, incadronate disodium for injection, and oxycodone hydrochloride sustained-release tablets; despite this, his pain remained poorly controlled. The patient was admitted to hospital with a pain score of 8/10. Other symptoms at presentation included fatigue, anorexia, distress and insomnia. A hydromorphone PCA was initiated, which led to a rapid improvement in the patient's pain. The patient died peacefully 17 days later; his family was highly satisfied.

Conclusions:

Older patients with cancer experience pain in myriad ways. Patients with advanced cancer pain should receive safe, rapid, and effective pain relief. Hydromorphone-based PCA therapies may provide a valuable therapeutic option for individuals with malignant pain.

01 Mar 2024·Archiv der Pharmazie

Dendrobium officinale polysaccharides—chemical properties and pharmacodynamic effects on the airways in experimental conditions

Article

Author: Matulová, Mária ; Mažerik, Jozef ; Capek, Peter ; Uhliariková, Iveta ; Kocmálová, Michaela ; Šutovská, Martina

Abstract:

The study aimed to analyze the effects of Dendrobium polysaccharides on the cough and airway reactivity and compare them with the effects of clinically used antitussives (codeine phosphate and butamirate citrate) and bronchodilators (salbutamol), using the guinea pig test system. Dendrobium officinale polysaccharides contained proteins (4.0 wt%) and phenolic compounds (1.7 wt%) with a molecular weight of 25,000 g/mol. The sugar analysis revealed a dominance of glucose (93.7 wt%) and a lesser amount of mannose (5.1 wt%) while other sugar quantities were negligible. Methylation analysis indicated the presence of highly branched polysaccharides. Glucose was found mainly as terminal, 1,4‐ and 1,6‐linked. Furthermore, some 1,4‐ and 1,6‐linked glucose units were found branched at O2, O3, and O6/O4. Mannose was terminal and 1,4‐linked. NMR spectra signals indicate the presence of the (1→4)‐linked α‐d‐glucan, (1→4)‐linked β‐d‐glucan branched at position O6, (1→6)‐linked β‐d‐glucan branched at position O3 and (1→4)‐linked glucomannan. Pharmacological studies showed statistically significant antitussive activity of Dendrobium polysaccharides, exceeding the effect of clinically used antitussives, which may be partially associated with confirmed bronchodilation and the ability of polysaccharides to increase the threshold of cough receptor activation. Dendrobium polysaccharides may increase the possibility of symptomatic treatment of cough, especially in asthmatics.

01 Mar 2024·Legal medicine (Tokyo, Japan)

Plastic bag suffocation and codeine overdose: An unusual case of complex suicide and review of the literature

Review

Author: Franceschetti, Lorenzo ; Tarozzi, Ilaria ; Rizzo, Amalia ; Bugelli, Valentina ; Chericoni, Silvio

The term "planned complex suicide" refers to cases where two or more suicide methods are applied simultaneously. Plastic bag suffocation is a suicidal method commonly combined with self-poisoning by inhalation of volatile compounds or pharmacological substances at poisoning dosage. A 67-year-old woman was found dead on the couch. The head was wrapped in a plastic bag knotted at the front of the neck. No signs of struggle were present on the scene. In the fireplace, there were two blisters of acetaminophen/codeine phosphate tablets. Postmortem examination showed congestion of the face and the neck and pulmonary edema with patchy emphysema. There was no evidence of physical duress. Toxic levels of codeine were detected in the blood. The death was related to a complex suicide involving codeine overdose and asphyxia by plastic bag suffocation. The hypoxic/cardioinhibitory effects of plastic bag suffocation combined to codeine-induced deep reduction of respiratory rate, making the suicide hypothesis the more likely scenario. In order to assess what elements contribute to postmortem diagnosis in complex suicides with plastic bag suffocation, a review of the forensic literature published between 2002 and 2022 was performed. This article emphasizes the complexity of diagnosing deaths involving plastic bag suffocation in suicides, particularly when combined with other methods like inert gas inhalation or drug intake. It underscores the importance of comprehensive toxicological analyses, careful scene examination, and histological studies, not forgetting a thorough comparative analysis of the existing literature, to accurately determine the cause and manner of death in such cases.

News (Medical) associated with Codeine Phosphate Hydrate

01 May 2024

·www.prnewswire.com

Opioid Withdrawal Syndrome Drug Market to Surge at a CAGR of 4.0% by 2034 | DelveInsight

According to DelveInsight's analysis, the current developmental pipeline for opioid withdrawal syndrome has multiple players; several companies have initiated clinical trials investigating new treatment options or studying how to use existing treatment options better. The dynamics of the opioid withdrawal syndrome market are also anticipated to change in the coming years, owing to the rise in healthcare spending globally. LAS VEGAS, May 1, 2024 /PRNewswire/ -- DelveInsight's Opioid Withdrawal Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, opioid withdrawal syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Opioid Withdrawal Syndrome Market Report According to DelveInsight's analysis, the market size for opioid withdrawal syndrome reached USD 1.3 billion in 2022 across the 7MM. Among the 7MM, the US captured the highest market in 2022, covering a total of 90% market, followed by the UK, which is anticipated to grow during the forecast period (2023–2034). In the US, the market mainly consisted of opioid agonist-antagonist, Alpha-2 adrenergic agonists and others, which generated nearly USD 1.1 million in 2022. According to DelveInsight estimations, nearly 9 million cases with long-term opioid usage were found in 2022 in the 7MM. Leading opioid withdrawal syndrome companies such as DemeRx IB, Inc., atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., and others are developing novel opioid withdrawal syndrome drugs that can be available in the opioid withdrawal syndrome market in the coming years. The promising opioid withdrawal syndrome therapies in the pipeline include DMX-1002 (Ibogaine HCl), MN-166, BXCL501 , and others. Discover which therapies are expected to grab the major opioid withdrawal syndrome market share @ Opioid Withdrawal Syndrome Market Report Opioid Withdrawal Syndrome Overview Opioid withdrawal is a set of symptoms that occurs when opioids (such as µ-receptor agonists) are suddenly stopped, their use is reduced, or they are no longer taken for treatment. This can also happen when an opioid antagonist (like naltrexone or naloxone) or, in some cases, a partial opioid agonist (such as buprenorphine) is given to someone who has become physically dependent on opioids due to regular and persistent use. There isn't a specific test to diagnose opioid withdrawal, but it's important to conduct urine toxicology tests to rule out withdrawal from other drugs or combinations of drugs. Urine tests usually detect most opioids like morphine, heroin, codeine, oxycodone, and propoxyphene for about 12 to 36 hours after their use. However, methadone, buprenorphine, and LAAM (L-alpha-acetylmethadol) won't show up in standard urine tests for opioids and need specific testing. Additionally, urine tests for other substances like marijuana, cocaine, benzodiazepines, and amphetamines may often show positive results in opioid users. Other tests such as ECG, complete blood count (CBC), blood alcohol levels, and basic metabolic panel (BMP) should also be conducted. The severity of opioid withdrawal is commonly assessed using the Clinical Opioid Withdrawal Scale (COWS). Opioid Withdrawal Syndrome Epidemiology Segmentation As per DelveInsight's estimations, the total number of cases with opioid withdrawal syndrome in the United States were approximately 7 million in 2022 and are projected to decrease during the forecast period. The opioid withdrawal syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Number of Opioid Misuse Cases Number of Cases with Long-term Opioid Usage Total Opioid Withdrawal Symptoms Cases Opioid Withdrawal Syndrome Treatment Market The management of opioid use disorder and opioid withdrawal syndrome are intricately linked since they tackle various facets of the same fundamental problem: dependency on opioids and the difficulties it brings. Opioid use disorder treatment is centered on enduring control and recovery from opioid addiction, whereas opioid withdrawal syndrome treatment mainly deals with the immediate symptoms that emerge when people try to lessen or stop their opioid use. A successful approach to handling OWS is frequently a vital part of OUD treatment, especially during the detoxification stage when individuals might undergo severe withdrawal symptoms. Drugs employed to ease OWS can also contribute to treating OUD by aiding individuals in moving from reliance on opioids towards stability and eventual abstinence. These medications not only alleviate withdrawal signs but also diminish cravings, facilitating individuals' participation in behavioral therapies and other components of comprehensive OUD treatment. The management strategy for OWS varies depending on how severe the symptoms are for the person. When the withdrawal symptoms are mild, patients are advised to focus on staying hydrated by drinking at least 2–3 liters of water each day. Additionally, taking vitamin B and C supplements may be helpful in maintaining overall health. Generally, managing mild symptoms involves providing symptomatic treatment and supportive care, aiming to ease discomfort and ensure the patient's well-being during this period. In instances of greater severity, drugs such as methadone or codeine phosphate might be contemplated, especially for those needing detoxification from opioids with longer-lasting effects. These medications can ease withdrawal symptoms and diminish cravings, but cautious supervision and dosage adjustments are vital to ensure safety and efficacy. To know more about opioid withdrawal syndrome treatment guidelines, visit @ Opioid Withdrawal Syndrome Management Opioid Withdrawal Syndrome Pipeline Therapies and Key Companies DMX-1002 (Ibogaine HCl): DemeRx IB, Inc./atai Life Sciences MN-166: MediciNova BXCL501: BioXcel Therapeutics Inc. Learn more about the FDA-approved drugs for opioid withdrawal syndrome @ Drugs for Opioid Withdrawal Syndrome Treatment Opioid Withdrawal Syndrome Market Dynamics The dynamics of the opioid withdrawal syndrome market are expected to change in the coming years. Globally, the recognition of the opioid crisis and the necessity for effective treatments, including medications and behavioral therapies, has prompted pharmaceutical companies to invest in research and development, while government initiatives prioritize opioid withdrawal management, fostering opioid withdrawal syndrome market growth and opportunities for companies. The shift towards precision medicine also offers possibilities for developing targeted treatments, addressing the high prevalence of opioid addiction, and creating significant market demand for withdrawal syndrome treatments, potentially leading to substantial growth with the introduction of therapies featuring novel mechanisms, alongside the dominance of buprenorphine-based products in the current and emerging opioid withdrawal syndrome market. Furthermore, many potential therapies are being investigated for the treatment of opioid withdrawal syndrome, and it is safe to predict that the treatment space will significantly impact the opioid withdrawal syndrome market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the opioid withdrawal syndrome market in the 7MM. However several factors may impede the growth of the opioid withdrawal syndrome market. The stigma surrounding opioid addiction and withdrawal persists, potentially dissuading individuals from pursuing treatment or utilizing the resources available to them, despite advancements. The range of treatments for opioid withdrawal syndrome is still somewhat limited, necessitating more effective and accessible options. Stringent regulatory requirements and lengthy approval processes could delay the introduction of new OWS therapies to the market, hampering innovation, while economic downturns or changes in healthcare policies might impact funding for opioid addiction treatment programs and access to care, posing a threat to the OWS market and potentially compromising patient care and therapeutic effectiveness. Moreover, opioid withdrawal syndrome treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the opioid withdrawal syndrome market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the opioid withdrawal syndrome market growth. Scope of the Opioid Withdrawal Syndrome Market Report Therapeutic Assessment: Opioid Withdrawal Syndrome current marketed and emerging therapies Opioid Withdrawal Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Opioid Withdrawal Syndrome Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Opioid Withdrawal Syndrome Market Access and Reimbursement Discover more about opioid withdrawal syndrome drugs in development @ Opioid Withdrawal Syndrome Clinical Trials Table of Contents Related Reports Opioid Withdrawal Syndrome Pipeline Opioid Withdrawal Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key opioid withdrawal syndrome companies, including Chiesi Farmaceutici S.p.A., BioXcel Therapeutics, Aphios Pharmaceutical, among others. Opioid Withdrawal Syndrome Epidemiology Opioid Withdrawal Syndrome Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted opioid withdrawal syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Opioid Use Disorder Market Opioid Use Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key opioid use disorder companies, including Braeburn Pharmaceuticals, BioXcel Therapeutics, MediciNova, AstraZeneca, Cerevel Therapeutics, LLC, Indivior Inc., Aptinyx, among others. Opioid Dependence Market Opioid Dependence Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key opioid dependence companies, including GW Pharmaceuticals, Opiant Pharmaceuticals, ATAI Life Sciences, C4X Discovery, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

100 Deals associated with Codeine Phosphate Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Codeine Phosphate Hydrate	R05DA04	DB00318

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Pain	GB	Wockhardt UK Ltd.	20 May 1981
Diarrhea	GB	Wockhardt UK Ltd.	20 May 1981
Anesthesia	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Cough	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Pain	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04066426 (CTgov)	Phase 4	Soft tissue rheumatism \| Myofascial Pain Syndromes	200	naproxen sodium+paracetamol+dexamethasone+codeine phosphate (Naproxen Sodium+Codeine Phosphate)	yatulukwiw(qoxpyjcbbz) = hdbfgmjrml qvsrjbupco (enrogflwex, vytoglejyv - yxnlkrkwxy) View more	-	15 Feb 2021
				naproxen sodium+paracetamol+dexamethasone+codeine phosphate (Naproxen Sodium+Dexamethasone)	yatulukwiw(qoxpyjcbbz) = trkspiuvlc qvsrjbupco (enrogflwex, uwhkhvkext - ghicezkuii) View more
ACR2017	Not Applicable	Fibromyalgia	26,516	Opioid exposure	xmznptoete(lzglxncepd) = ljyzvpddjv xsbovconxc (wsyeyvqhrh )	Negative	08 Nov 2017
				No opioid exposure	xmznptoete(lzglxncepd) = pgoqpzuqkv xsbovconxc (wsyeyvqhrh )
NCT01055704 (CTgov)	Phase 4	Gastrointestinal motility disorder	48	Placebo + placebo	nkeyrvzkfd(vaorjvuzhe) = qbvnrbphnt xfituxwwbi (vvijilhtuu, qicynwsuoa - zkbewqwdok) View more	-	08 Aug 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis